{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:38:55Z","timestamp":1786628335647,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["americanjournalofsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Surgery"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.amjsurg.2026.117099","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:22:40Z","timestamp":1781104960000},"page":"117099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Outcomes of peptide receptor radionuclide therapy after progression following hepatic cytoreductive operation for neuroendocrine tumors"],"prefix":"10.1016","volume":"260","author":[{"given":"Kaiya","family":"Kozuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Aaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Pommier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.amjsurg.2026.117099_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.amjsurg.2026.117099_bib2","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.amjsurg.2026.117099_bib3","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.surg.2014.08.009","article-title":"Expanded criteria for carcinoid liver debulking: maintaining survival and increasing the number of eligible patients","volume":"156","author":"Graff-Baker","year":"2014","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.amjsurg.2026.117099_bib4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.surg.2017.05.030","article-title":"Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors","volume":"163","author":"Morgan","year":"2018","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.amjsurg.2026.117099_bib5","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.surg.2018.04.070","article-title":"Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases","volume":"165","author":"Scott","year":"2019","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.amjsurg.2026.117099_bib6","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.surg.2015.05.040","article-title":"Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy?","volume":"159","author":"Maxwell","year":"2016","journal-title":"Surgery"},{"key":"10.1016\/j.amjsurg.2026.117099_bib7","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.amjsurg.2026.117099_bib8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.surg.2015.05.040","article-title":"Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy?","volume":"159","author":"Maxwell","year":"2016","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.amjsurg.2026.117099_bib9","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1245\/s10434-024-16463-7","article-title":"Peptide receptor radionuclide therapy improves survival in patients who progress after resection of gastroenteropancreatic neuroendocrine tumors","volume":"32","author":"Borbon","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"10446","key":"10.1016\/j.amjsurg.2026.117099_bib10","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.amjsurg.2026.117099_bib11","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","article-title":"Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on outcomes from the NETTER-1 study: post hoc analyses of a phase 3 trial of 177Lu-Dotatate in midgut neuroendocrine tumours","volume":"47","author":"Strosberg","year":"2020","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"2","key":"10.1016\/j.amjsurg.2026.117099_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjsurg.2026.117099_bib13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.surg.2020.03.030","article-title":"Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumors","volume":"169","author":"Wonn","year":"2021","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.amjsurg.2026.117099_bib14","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.surg.2014.08.009","article-title":"Expanded criteria for carcinoid liver debulking: maintaining survival and increasing the number of eligible patients","volume":"156","author":"Graff-Baker","year":"2014","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.amjsurg.2026.117099_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Europ J Cancer (Oxford, England : 1990)"},{"issue":"Suppl S","key":"10.1016\/j.amjsurg.2026.117099_bib16","first-page":"S138","article-title":"Impact of immortal person-time and time scale in comparative effectiveness research of chronic medication users: Bias and correction strategies","volume":"66","author":"Setoguchi","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"10.1016\/j.amjsurg.2026.117099_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.24750","article-title":"Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States","volume":"4","author":"Xu","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.amjsurg.2026.117099_bib18","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/SLA.0000000000002809","article-title":"Resection of the primary gastrointestinal neuroendocrine tumor improves survival with or without liver treatment","volume":"270","author":"Lewis","year":"2019","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.amjsurg.2026.117099_bib19","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.amjsurg.2021.03.036","article-title":"Evaluation of the prognosis for N2 status in patients with small bowel neuroendocrine tumors","volume":"221","author":"Wonn","year":"2021","journal-title":"Am J Surg"}],"container-title":["The American Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961026002849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961026002849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:06:46Z","timestamp":1786626406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002961026002849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":19,"alternative-id":["S0002961026002849"],"URL":"https:\/\/doi.org\/10.1016\/j.amjsurg.2026.117099","relation":{},"ISSN":["0002-9610"],"issn-type":[{"value":"0002-9610","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of peptide receptor radionuclide therapy after progression following hepatic cytoreductive operation for neuroendocrine tumors","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjsurg.2026.117099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117099"}}